CANDEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CANDEX (CANDEX).
Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.
| Metabolism | Primarily metabolized by CYP2C9 to an inactive metabolite; also undergoes O-deethylation. Minimal hepatic metabolism, primarily excreted unchanged in bile and urine. |
| Excretion | Primarily hepatic metabolism via CYP2C9, with <1% excreted unchanged in urine. Approximately 70-80% eliminated in feces as metabolites, 20-30% in urine as metabolites. |
| Half-life | Terminal elimination half-life is 20-30 hours (mean 24 hours) in adults; prolonged in hepatic impairment (up to 50 hours) and requires dose adjustment. |
| Protein binding | 99% bound to albumin (primarily), also to alpha-1-acid glycoprotein. |
| Volume of Distribution | Extensive: 1.5-2 L/kg, indicating wide distribution into tissues including skin, nails, and adipose tissue. Accumulates in stratum corneum and nails. |
| Bioavailability | Oral: 99% (well absorbed); food does not affect absorption. No IV formulation due to poor water solubility; not administered topically for systemic effects. |
| Onset of Action | Oral: 7-10 days for full antifungal effect (based on dermatophyte infections). Intravenous: Not typically used; onset similar to oral due to slow accumulation. For esophageal candidiasis: clinical response in 5-7 days. |
| Duration of Action | Sustained for 48-72 hours after last dose due to long half-life; treatment duration varies by indication (e.g., 2 weeks for vaginal candidiasis, 4-6 weeks for dermatophyte infections). |
| Action Class | Fungal ergosterol synthesis inhibitor |
| Brand Substitutes | Daad-Raaath Cream, Rizole DS Cream, Clotik Cream, Czson Cream, Clocip Cream 15 gm for Skin Infections, Imidil Cream, Clotrex Cream, Colocaz 1% Cream |
Adults: 150 mg orally once daily
| Dosage form | CREAM |
| Renal impairment | CrCl 30-60 mL/min: 100 mg once daily; CrCl 15-29 mL/min: 50 mg once daily; CrCl <15 mL/min: 50 mg every 48 hours |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 100 mg once daily; Child-Pugh C: not recommended |
| Pediatric use | Not established for children <18 years of age |
| Geriatric use | No specific adjustment required; consider renal function and potential for increased sensitivity |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CANDEX (CANDEX).
| Breastfeeding | Excretion into breast milk is unknown; limited data may be available for similar ARBs but M/P ratio is not established. Due to risk of neonatal renal effects, use during breastfeeding is not recommended, especially in preterm infants or those with renal impairment. Alternative agents preferred. |
| Teratogenic Risk | Teratogenic risk profile for Candesartan (CANDEX) is based on its mechanism as an angiotensin II receptor blocker (ARB). First trimester: No increased risk of major congenital malformations from first-trimester exposure based on human data, but animal studies show fetal toxicity at high doses. Second and third trimesters: Known to cause fetal renal dysfunction, oligohydramnios, skull ossification defects, and neonatal renal failure. Use is contraindicated in pregnancy, especially after 20 weeks gestation. |
■ FDA Black Box Warning
Fetal toxicity: Drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.
| Serious Effects |
["Hypersensitivity to candesartan or any component","Concomitant use with aliskiren in patients with diabetes","Pregnancy"]
| Precautions | ["Fetal toxicity","Hypotension in volume-depleted patients","Renal function impairment","Hyperkalemia","Avoid concomitant use with aliskiren in patients with diabetes"] |
| Food/Dietary | No significant food interactions. Grapefruit juice does not interact. Avoid salt substitutes with potassium. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and renal function (serum creatinine, potassium). Fetal monitoring includes ultrasound assessment of amniotic fluid volume, fetal growth, and renal anatomy if exposed after 20 weeks. Neonatal monitoring for hypotension, oliguria, and hyperkalemia is required postpartum. |
| Fertility Effects | No specific data on human fertility; animal studies did not show adverse effects on fertility. However, ARBs may theoretically affect sperm function via angiotensin II pathways, but clinical significance is unknown. Use in women of childbearing potential requires contraception counseling. |
| Clinical Pearls |
| Candesartan is contraindicated in pregnancy (category D). Monitor renal function and electrolytes, especially in renal artery stenosis, heart failure, or volume depletion. May cause hypotension, especially in CHF patients. Dual blockade with ACEi increases risk of hyperkalemia and renal impairment. |
| Patient Advice | Take exactly as prescribed, usually once daily. · Avoid potassium supplements or salt substitutes containing potassium without medical advice. · If you become pregnant, stop taking and contact your doctor immediately. · May cause dizziness or lightheadedness; avoid driving until you know how you react. · Report any signs of angioedema (swelling of face, lips, throat) or fainting. · Stay hydrated, especially if experiencing diarrhea or vomiting. |